Key statistics
On Friday, Novo Nordisk A/S (NVON:MEX) closed at 2,216.06, -19.83% below its 52-week high of 2,764.09, set on Jun 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2,189.00 |
---|---|
High | 2,242.79 |
Low | 2,189.00 |
Bid | 2,200.00 |
Offer | 2,900.00 |
Previous close | 2,201.51 |
Average volume | 1.28k |
---|---|
Shares outstanding | 3.39bn |
Free float | 2.11bn |
P/E (TTM) | 38.92 |
Market cap | 390.14bn USD |
EPS (TTM) | 2.96 USD |
Annual div (ADY) | 26.96 MXN |
---|---|
Annual div yield (ADY) | 1.22% |
Div ex-date | Aug 16 2024 |
Div pay-date | Aug 26 2024 |
Data delayed at least 20 minutes, as of Oct 04 2024 20:58 BST.
More ▼
Announcements
- Novo Nordisk A/S – Share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
- Novo Nordisk A/S: Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Novo Nordisk's sales increased by 24% in Danish kroner and by 25% at constant exchange rates to DKK 133.4 billion in the first six months of 2024
- European regulatory authority adopts a positive opinion for an update of the Wegovy® label to reflect risk reduction of major adverse cardiovascular events
- Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec
- Novo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment loss
- Novo Nordisk announces 4.1 billion USD investment to expand US manufacturing capacity adline
More ▼